Trial Profile
Pharmacokinetics and Relative Bioavailability of XmAb®5871 Administered Either Intravenously or Subcutaneously
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 02 Jan 2024
Price :
$35
*
At a glance
- Drugs Obexelimab (Primary) ; Obexelimab (Primary)
- Indications Autoimmune disorders; Rheumatoid arthritis; Systemic lupus erythematosus
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Xencor
- 15 Nov 2023 Results of a PopPK model analysis from four clinical trials: a first-in-human, single-ascending dose study in healthy volunteers; 2) a multiple-ascending dose study in patients with RA; 3) an open-label study in patients with IgG4-RD; and 4) a PK and relative bioavailability study.
- 14 Nov 2022 Results assessing the pharmacokinetics (PK), receptor occupancy (RO), and pharmacodynamics (PD) of obexelimab following intravenous (IV) administration in adult healthy volunteers and in patients with rheumatoid arthritis presented at the ACR Convergence 2022
- 09 May 2017 Results published in a Xencor media release.